{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:09:16Z","timestamp":1793372956723,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40273-022-01168-0","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T04:02:41Z","timestamp":1656734561000},"page":"699-714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US"],"prefix":"10.1007","volume":"40","author":[{"given":"Hardik","family":"Goswami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Alsumali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Duke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Puenpatom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,2]]},"reference":[{"key":"1168_CR1","unstructured":"World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int\/table. Accessed 4 Feb 2022."},{"key":"1168_CR2","unstructured":"CNBC. Uninsured Americans could be facing nearly $75,000 in medical bills if hospitalized for coronavirus. 2020. https:\/\/www.cnbc.com\/2020\/04\/01\/covid-19-hospital-bills-could-cost-uninsured-americans-up-to-75000.html. Accessed 2 Feb 2022."},{"key":"1168_CR3","unstructured":"McKinsey & Company. Understanding the hidden costs of COVID-19\u2019s potential impact on US healthcare. 2020. https:\/\/www.mckinsey.com\/industries\/healthcare-systems-and-services\/our-insights\/understanding-the-hidden-costs-of-covid-19s-potential-impact-on-us-healthcare. Accessed 2 Feb 2022."},{"key":"1168_CR4","unstructured":"CNN Health. An average Covid-19 hospitalization costs Medicare about 150 times more than it does to vaccinate one beneficiary. 2021. https:\/\/edition.cnn.com\/2021\/09\/09\/health\/covid-19-hospitalization-cost-vaccination\/index.html."},{"key":"1168_CR5","unstructured":"Centers for Disease Control and Prevention. Different COVID-19 Vaccines. 1 September 2021. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/different-vaccines.html."},{"issue":"7862","key":"1168_CR6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/d41586-021-01505-x","volume":"594","author":"H Ledford","year":"2021","unstructured":"Ledford H. Six months of COVID vaccines: what 1.7 billion doses have taught scientists. Nature. 2021;594(7862):264\u2013167.","journal-title":"Nature"},{"issue":"10","key":"1168_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003902","volume":"105","author":"S Anjan","year":"2021","unstructured":"Anjan S, et al. Breakthrough COVID-19 infections after mRNA vaccination in solid organ transplant recipients in Miami, Florida. Transplantation. 2021;105(10): e139.","journal-title":"Transplantation"},{"issue":"11","key":"1168_CR8","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S1473-3099(21)00558-2","volume":"21","author":"PV Juthani","year":"2021","unstructured":"Juthani PV, et al. Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect Dis. 2021;21(11):1485\u20136.","journal-title":"Lancet Infect Dis"},{"issue":"20","key":"1168_CR9","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1001\/jama.2021.19499","volume":"326","author":"MW Tenforde","year":"2021","unstructured":"Tenforde MW, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021;326(20):2043\u201354.","journal-title":"JAMA"},{"key":"1168_CR10","unstructured":"The World Bank. COVID-19 to Plunge Global Economy into Worst Recession since World War II. https:\/\/www.worldbank.org\/en\/news\/press-release\/2020\/06\/08\/covid-19-to-plunge-global-economy-into-worst-recession-since-world-war-ii#:~:text=According%20to%20World%20Bank%20forecasts,shrink%20by%205.2%25%20this%20year.&text=That%20would%20represent%20the%20deepest,June%202020%20Global%20Economic%20Prospects. Accessed 8 June 2020."},{"key":"1168_CR11","unstructured":"Congressional Budget Office. Comparison of CBO\u2019s May 2020 Interim Projections of Gross Domestic Product and Its January 2020 Baseline Projections. https:\/\/www.cbo.gov\/publication\/56376. Accessed 1 June 2020."},{"key":"1168_CR12","unstructured":"Congressional Budget Office. Budgetary Effects of the 2020 Coronavirus Pandemic. 2020. https:\/\/www.cbo.gov\/publication\/56388. Accessed 2 Feb 2022."},{"key":"1168_CR13","unstructured":"United States Department of Labor. Unemployment insurance weekly claims. 2020; https:\/\/oui.doleta.gov\/unemploy\/claims_arch.asp."},{"key":"1168_CR14","unstructured":"Office of the Actuary, Centers for Medicare & Medicaid Services. National Health Spending in 2020 Increases due to Impact of COVID-19 Pandemic. https:\/\/www.cms.gov\/newsroom\/press-releases\/national-health-spending-2020-increases-due-impact-covid-19-pandemic."},{"issue":"6","key":"1168_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"A Jayk Bernal","year":"2021","unstructured":"Jayk Bernal A, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2021;386(6):509\u201320.","journal-title":"N Engl J Med"},{"issue":"6","key":"1168_CR16","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1056\/NEJMe2117814","volume":"386","author":"R Whitley","year":"2022","unstructured":"Whitley R. Molnupiravir\u2014a step toward orally bioavailable therapies for Covid-19. N Engl J Med. 2022;386(6):592\u20133.","journal-title":"N Engl J Med"},{"key":"1168_CR17","unstructured":"GOV.UK. First oral antiviral for COVID-19, Lagevrio (molnupiravir), approved by MHRA. 2021. https:\/\/www.gov.uk\/government\/news\/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra. Accessed 2 Feb 2022."},{"key":"1168_CR18","unstructured":"US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults. 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain."},{"key":"1168_CR19","unstructured":"\u539a\u751f\u52b4\u50cd\u7701. \u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u6cbb\u7642\u85ac\u306e\u7279\u4f8b\u627f\u8a8d\u306b\u3064\u3044\u3066. https:\/\/www.mhlw.go.jp\/stf\/newpage_23047.html. Accessed 3 Dec 2021."},{"key":"1168_CR20","unstructured":"The New York Times. See How Vaccinations Are Going in Your County and State. https:\/\/www.nytimes.com\/interactive\/2020\/us\/covid-19-vaccine-doses.html. Accessed 7 Feb 2022."},{"key":"1168_CR21","unstructured":"Centers for Disease Control and Prevention. COVID-19 Vaccine Booster Shots. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/booster-shot.html. Accessed 2 Feb 2022."},{"issue":"5","key":"1168_CR22","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMc2119270","volume":"386","author":"S Collie","year":"2022","unstructured":"Collie S, et al. Effectiveness of BNT162b2 vaccine against omicron variant in South Africa. N Engl J Med. 2022;386(5):494\u20136.","journal-title":"N Engl J Med"},{"issue":"8","key":"1168_CR23","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1007\/s11606-022-07496-3","volume":"37","author":"DM Dudzinski","year":"2022","unstructured":"Dudzinski DM. Moral outrage toward willfully unvaccinated COVID-19 patients. J Gen Intern Med. 2022;37(8):2070\u20131.","journal-title":"J Gen Intern Med"},{"key":"1168_CR24","unstructured":"TriNetX. Coronavirus. 2022. https:\/\/trinetx.com\/real-world-resources\/coronavirus\/."},{"key":"1168_CR25","unstructured":"Puenpatom A et al. Healthcare utilization, mortality, and care pathway among patients with COVID-19 in the US [Manuscript in preparation.]"},{"issue":"3","key":"1168_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13700","volume":"75","author":"E Atalla","year":"2021","unstructured":"Atalla E, et al. Readmissions among patients with COVID-19. Int J Clin Pract. 2021;75(3): e13700.","journal-title":"Int J Clin Pract"},{"issue":"7","key":"1168_CR27","first-page":"1","volume":"68","author":"E Arias","year":"2019","unstructured":"Arias E. United States Life Tables, 2017. Natl Vital Stat Rep. 2019;68(7):1\u201366.","journal-title":"Natl Vital Stat Rep"},{"key":"1168_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.584182","volume":"9","author":"KE Mason","year":"2021","unstructured":"Mason KE, et al. Age-adjusted associations between comorbidity and outcomes of COVID-19: a review of the evidence from the early stages of the pandemic. Front Public Health. 2021;9: 584182.","journal-title":"Front Public Health"},{"issue":"14","key":"1168_CR29","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1001\/jama.2020.2565","volume":"323","author":"Y Bai","year":"2020","unstructured":"Bai Y, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323(14):1406\u20137.","journal-title":"JAMA"},{"issue":"5","key":"1168_CR30","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","volume":"8","author":"X Yang","year":"2020","unstructured":"Yang X, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475\u201381.","journal-title":"Lancet Respir Med"},{"key":"1168_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2020.198043","volume":"286","author":"J Li","year":"2020","unstructured":"Li J, et al. Clinical features of familial clustering in patients infected with 2019 novel coronavirus in Wuhan, China. Virus Res. 2020;286: 198043.","journal-title":"Virus Res"},{"issue":"10223","key":"1168_CR32","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507\u201313.","journal-title":"Lancet"},{"key":"1168_CR33","unstructured":"EuroQol. EQ-5D-5L | Valuation | Crosswalk Index Value Calculator. 2019. https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about\/valuation-standard-value-sets\/crosswalk-index-value-calculator\/. Accessed 2 Feb 2022."},{"key":"1168_CR34","unstructured":"Merck & Co. Merck and Ridgeback Announce U.S. Government to Purchase 1.4 Million Additional Courses of Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults. https:\/\/www.merck.com\/news\/merck-and-ridgeback-announce-u-s-government-to-purchase-1-4-million-additional-courses-of-molnupiravir-an-investigational-oral-antiviral-medicine-for-the-treatment-of-mild-to-moderate-covid-19-in-a\/. Accessed 6 Nov 2021."},{"issue":"9","key":"1168_CR35","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796\u20137.","journal-title":"N Engl J Med"},{"key":"1168_CR36","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006."},{"issue":"7","key":"1168_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132421","volume":"10","author":"M Falk Hvidberg","year":"2015","unstructured":"Falk Hvidberg M, et al. The health-related quality of life for patients with myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS). PLoS\u00a0One. 2015;10(7): e0132421.","journal-title":"PLoS\u00a0One"},{"key":"1168_CR38","unstructured":"Institute for Clinical and Economic Review. Alternative Pricing Models for Remdesivir and Other Potential Treatments for COVID-19. https:\/\/icer.org\/wp-content\/uploads\/2020\/11\/ICER-COVID_Updated_Report_11102020.pdf. Accessed 10 Nov 2020."},{"issue":"3","key":"1168_CR39","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40271-021-00509-z","volume":"14","author":"S Poteet","year":"2021","unstructured":"Poteet S, Craig BM. QALYs for COVID-19: a comparison of US EQ-5D-5L value sets. Patient Patient Centered Outcomes Res. 2021;14(3):339\u201345.","journal-title":"Patient Patient Centered Outcomes Res"},{"issue":"4","key":"1168_CR40","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0272989X06290495","volume":"26","author":"PW Sullivan","year":"2006","unstructured":"Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Mak. 2006;26(4):410\u201320.","journal-title":"Med Decis Mak"},{"key":"1168_CR41","doi-asserted-by":"crossref","unstructured":"Hoshijima H, et al. Incidence of long-term post-acute sequelae of SARS-CoV-2 infection related to pain and other symptoms: a living systematic review and meta-analysis. MedRxiv. 2021.","DOI":"10.1101\/2021.04.08.21255109"},{"issue":"7862","key":"1168_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41586-021-03553-9","volume":"594","author":"Z Al-Aly","year":"2021","unstructured":"Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259\u201364.","journal-title":"Nature"},{"key":"1168_CR43","unstructured":"Premier. Premier Healthcare Database being used by National Institutes of Health to evaluate impact of COVID-19 on patients across the U.S. 2020. https:\/\/www.premierinc.com\/newsroom\/press-releases\/premier-healthcare-database-being-used-by-national-institutes-of-health-to-evaluate-impact-of-covid-19-on-patients-across-the-u-s. Accessed 2 Feb 2022."},{"key":"1168_CR44","unstructured":"Premier. Data that Informs and Performs. 2020. https:\/\/learn.premierinc.com\/white-papers\/premier-healthcare-database-whitepaper. Accessed 2 Feb 2022."},{"issue":"11","key":"1168_CR45","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1007\/s12325-021-01887-4","volume":"38","author":"RL Ohsfeldt","year":"2021","unstructured":"Ohsfeldt RL, et al. Inpatient Hospital Costs for COVID-19 patients in the United States. Adv Ther. 2021;38(11):5557\u201395.","journal-title":"Adv Ther"},{"key":"1168_CR46","unstructured":"Moore BJ, Liang L. Costs of Emergency Department Visits in the United States, 2017, in Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Agency for Healthcare Research and Quality (US); 2020."},{"key":"1168_CR47","unstructured":"Centers for Medicare & Medicaid Services. CMS Physician Fee Schedule (HCPCS code: 99205 for office visit of high complexity). https:\/\/www.cms.gov\/files\/document\/physician-fee-schedule-pfs-payment-officeoutpatient-evaluation-and-management-em-visits-fact-sheet.pdf. Accessed 11 Jan 2022."},{"key":"1168_CR48","unstructured":"US Bureau of Labor Statistics. Data Retrieval: Labor Force Statistics (CPS). 2015. https:\/\/www.bls.gov\/webapps\/legacy\/cpswktab3.htm. Accessed cited 2020."},{"key":"1168_CR49","unstructured":"Lewnard JA, et al. Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. medRxiv. 2022:2022.01.11.22269045."},{"issue":"4","key":"1168_CR50","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.ajpath.2022.01.007","volume":"192","author":"PA Christensen","year":"2022","unstructured":"Christensen PA, et al. Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the omicron variant of severe acute respiratory syndrome coronavirus 2 in Houston, Texas. Am J Pathol. 2022;192(4):642\u201352.","journal-title":"Am J Pathol"},{"key":"1168_CR51","unstructured":"Paredes MI, et al. Associations between SARS-CoV-2 variants and risk of COVID-19 hospitalization among confirmed cases in Washington State: a retrospective cohort study. medRxiv. 2022:2021.09.29.21264272."},{"issue":"11","key":"1168_CR52","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s40273-019-00844-y","volume":"37","author":"NC B\u00fcy\u00fckkaramikli","year":"2019","unstructured":"B\u00fcy\u00fckkaramikli NC, et al. TECH-VER: a verification checklist to reduce errors in models and improve their credibility. Pharmacoeconomics. 2019;37(11):1391\u2013408.","journal-title":"Pharmacoeconomics"},{"key":"1168_CR53","doi-asserted-by":"publisher","DOI":"10.7326\/M22-0729","author":"MG Johnson","year":"2022","unstructured":"Johnson MG, et al. Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19. Ann Internal Med. 2022. https:\/\/doi.org\/10.7326\/M22-0729.","journal-title":"Ann Internal Med"},{"key":"1168_CR54","unstructured":"Institute for Clinical and Economic Review. Special Assessment of Outpatient Treatments for COVID-19 Response to Public Comments on Draft Evidence Report. Institute for Clinical and Economic Review; 2022."},{"key":"1168_CR55","unstructured":"Yeung K, Whittington MD, Beinfeld M, Mohammed R, Wright A, Nhan E, et al. Special Assessment of Outpatient Treatments for COVID-19. Institute for Clinical and Economic Review; 2022."},{"issue":"10309","key":"1168_CR56","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","volume":"398","author":"SY Tartof","year":"2021","unstructured":"Tartof SY, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407\u201316.","journal-title":"Lancet"},{"issue":"1","key":"1168_CR57","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/S2666-5247(21)00306-2","volume":"3","author":"SY Wang","year":"2022","unstructured":"Wang SY, et al. Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era. Lancet Microbe. 2022;3(1):e4\u20135.","journal-title":"Lancet Microbe"},{"issue":"2","key":"1168_CR58","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1056\/NEJMoa2116063","volume":"386","author":"ES Rosenberg","year":"2022","unstructured":"Rosenberg ES, et al. Covid-19 vaccine effectiveness in New York State. N Engl J Med. 2022;386(2):116\u201327.","journal-title":"N Engl J Med"},{"key":"1168_CR59","unstructured":"Office of National Statistics. Coronavirus and the social impacts of \u2018long COVID\u2019 on people\u2019s lives in Great Britain: 7 April to 13 June 2021. 2021. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/articles\/coronavirusandthesocialimpactsoflongcovidonpeopleslivesingreatbritain\/7aprilto13june2021#well-being-loneliness-and-long-covid."},{"issue":"5","key":"1168_CR60","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/10408363.2020.1860895","volume":"58","author":"V Higgins","year":"2021","unstructured":"Higgins V, et al. COVID-19: from an acute to chronic disease? Potential long-term health consequences. Crit Rev Clin Lab Sci. 2021;58(5):297\u2013310.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"1168_CR61","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jad.2020.06.033","volume":"275","author":"Y-F Ma","year":"2020","unstructured":"Ma Y-F, et al. Prevalence of depression and its association with quality of life in clinically stable patients with COVID-19. J Affect Disord. 2020;275:145\u20138.","journal-title":"J Affect Disord"},{"issue":"3","key":"1168_CR62","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S2215-0366(20)30046-8","volume":"7","author":"Y-T Xiang","year":"2020","unstructured":"Xiang Y-T, et al. Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed. Lancet Psychiatry. 2020;7(3):228\u20139.","journal-title":"Lancet Psychiatry"},{"key":"1168_CR63","unstructured":"IHME COVID-19 Health Service Utilization Forecasting Team, Murray CJ. Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator-days and deaths by US state in the next 4 months. MedRxiv. 2020."},{"issue":"5","key":"1168_CR64","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jval.2021.12.005","volume":"25","author":"RC Moon","year":"2022","unstructured":"Moon RC, Brown H, Rosenthal N. Healthcare resource utilization of patients with COVID-19 visiting US Hospitals. Value Health. 2022;25(5):751\u201360.","journal-title":"Value Health"},{"issue":"46","key":"1168_CR65","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.15585\/mmwr.mm7046a5","volume":"70","author":"G French","year":"2021","unstructured":"French G, et al. Impact of hospital strain on excess deaths during the COVID-19 pandemic\u2014United States, July 2020\u2013July 2021. Morb Mortal Wkly Rep. 2021;70(46):1613.","journal-title":"Morb Mortal Wkly Rep"},{"key":"1168_CR66","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jhin.2021.04.018","volume":"114","author":"HC Maltezou","year":"2021","unstructured":"Maltezou HC, et al. Costs associated with COVID-19 in healthcare personnel in Greece: a cost-of-illness analysis. J Hosp Infect. 2021;114:126\u201333.","journal-title":"J Hosp Infect"},{"issue":"1","key":"1168_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12960-020-00544-1","volume":"18","author":"N Salari","year":"2020","unstructured":"Salari N, et al. The prevalence of stress, anxiety and depression within front-line healthcare workers caring for COVID-19 patients: a systematic review and meta-regression. Hum Resour Health. 2020;18(1):1\u201314.","journal-title":"Hum Resour Health"},{"issue":"27","key":"1168_CR68","doi-asserted-by":"publisher","first-page":"15530","DOI":"10.1073\/pnas.2007658117","volume":"117","author":"G Bonaccorsi","year":"2020","unstructured":"Bonaccorsi G, et al. Economic and social consequences of human mobility restrictions under COVID-19. Proc Natl Acad Sci. 2020;117(27):15530\u20135.","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"1168_CR69","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2016632118","volume":"118","author":"O Giuntella","year":"2021","unstructured":"Giuntella O, et al. Lifestyle and mental health disruptions during COVID-19. Proc Natl Acad Sci. 2021;118(9): e2016632118.","journal-title":"Proc Natl Acad Sci"}],"updated-by":[{"DOI":"10.1007\/s40273-023-01263-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000}}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01168-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-022-01168-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01168-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T02:39:13Z","timestamp":1700793553000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-022-01168-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1168"],"URL":"https:\/\/doi.org\/10.1007\/s40273-022-01168-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40273-023-01263-w","asserted-by":"object"}]},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"19 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40273-023-01263-w","URL":"https:\/\/doi.org\/10.1007\/s40273-023-01263-w","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hardik Goswami, Adnan Alsumali and Amy Puenpatom are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, who may own stock and\/or stock options in Merck & Co., Inc., Kenilworth, NJ, USA. Yiling Jiang is an employee of MSD (UK) Ltd, who may own stock and\/or stock options in Merck & Co., Inc., Kenilworth, NJ, USA. Matthias Schindler is an employee of MSD (Switzerland) Ltd., who may own stock and\/or stock options in Merck & Co., Inc., Kenilworth, NJ, USA. Elizabeth Duke was the site principal investigator for the clinical trial from which these data were drawn and for the ongoing MK4482-013 clinical trial studying molnupiravir for prevention of COVID-19 in household contacts. Her institution, Fred Hutchinson Cancer Research Center, received funding from Merck & Co., Inc. to conduct these studies but the funding was not tied to study outcomes. Joshua Cohen received compensation from Merck & Co., Inc. as a consultant for this work. Andrew Briggs received compensation from Merck & Co., Inc. as a consultant for this work. He has also been contracted by Bayer, Eisai, Janssen, Novartis, Sword Health, Amgen, and Daichii Sankyo and received compensation outside of the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This was a cost-effectiveness study and no ethics approval was required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Consent to participate was not required for this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent to publish was not required for this study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}